Dr Gaétan Burgio, Department of Immunology, The John Curtin School of Medical Research, ANU
Malaria infection is the third lethal disease worldwide and a curative treatment is desperately needed. Resistance to the malarial parasite to all known antimalarial drugs is now the norm. Parasites develop resistance through modification of both target and intra-parasitic drug concentrations. Malarial parasites have also led to selected mutations showing an increase in the gene pool of human population living in endemic regions and these mutations render the human population more resistant to malaria. Our group has developed various strategies to develop new therapies that will bypass these mechanisms of resistance and mimic these genetic changes as seen in human populations living in endemic areas. I will discuss these discoveries and the latest technologies in our field.
Dr Burgio was born in France and completed his education at Paris. He graduated from the Faculty of Medicine Xavier Bichat in Paris in 2002 with a Medical Doctor Degree, receiving a bronze medal award for outstanding performances during his medical studies. He worked as a consultant in an emergency department at Paris. He completed his PhD in 2008 from Pasteur Institute in France and migrated to Australia to join Professor Simon Foote as a postdoctoral researcher. In 2012 he was appointed as a senior research fellow at Macquarie University investigating the host response to the malaria parasite. In 2015 he was appointed as a Senior Research Fellow, group leader at the John Curtin of Medical Research and the head of the transgenesis core facility at the Australian Phenomics Facility to establish a research program of the host pathogens interaction and genome engineering technologies. His research is supported from the NHMRC.